EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access · CC BY 4.0

Ixazomib Versus Placebo as Postinduction Maintenance Therapy in Newly Diagnosed Multiple Myeloma Patients: An Analysis by Age and Frailty Status of the TOURMALINE-MM4 Study

Sara Bringhen, Luděk Pour, Reuben Benjamin, Sebastian Grosicki, Chang-Ki Min, Danielle Leao C de Farias, Alexander Vorog, Richard J Labotka, Bingxia Wang, Dasha Cherepanov, Lauren E Cain, Sudhakar Manne und 2 weitere

Clinical Lymphoma Myeloma and Leukemia · 2023

DOI: 10.1016/j.clml.2023.03.007 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2023. Verfasst von Sara Bringhen und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, SSD Clinical Trial in Oncoematologia e Mieloma Multiplo, University of Torino, Azienda Ospedaliero-Universitaria Città della …. Hauptthemen laut MEDLINE: Frailty, Multiple Myeloma. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AHRQ HHS, Takeda Pharmaceutical Company, Millennium Pharmaceuticals Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The TOURMALINE-MM4 trial demonstrated a significant and clinically meaningful progression-free survival (PFS) benefit with ixazomib versus placebo as postinduction maintenance in nontransplant, newly-diagnosed multiple myeloma patients, with a manageable and well-tolerated toxicity profile. MATERIALS AND METHODS: In this subgroup analysis, efficacy and safety were assessed by age (< 65, 65-74, and ≥ 75 years) and frailty status (fit, intermediate-fit, and frail). RESULTS: In this analysis, PFS benefit with ixazomib versus placebo was seen across age subgroups, including patients aged < 65 years (hazard ratio [HR], 0.576; 95% confidence interval [CI], 0.299-1.108; P = .095), 65-74 years (HR, 0.615; 95% CI, 0.467-0.810; P < .001), and ≥ 75 years (HR, 0.740; 95% CI, 0.537-1.019; P = .064). PFS benefit was also seen across frailty subgroups, including fit (HR, 0.530; 95% CI, 0.387-0.727; P < .001), intermediate-fit (HR, 0.746; 95% CI, 0.526-1.058; P = .098), and frail (HR, 0.733; 95% CI, 0.481-1.117; P = .147) patients. With ixazomib versus placebo, rates of grade ≥ 3 treatment-emergent adverse events (TEAEs; 28-44% vs. 10-36%), serious TEAEs (15-29% vs. 3-29%), and discontinuation due to TEAEs (7-19% vs. 5-11%) were higher or similar across age and frailty subgroups, and generally somewhat higher in older age groups and intermediate-fit/frail patients in both arms. Treatment with ixazomib versus placebo did not adversely affect patient-reported quality-of-life scores across age and frailty status subgroups. CONCLUSION: Ixazomib is a feasible and effective maintenance option for prolonging PFS across this heterogeneous patient population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FrailtyMultiple MyelomaAgedHumansAntineoplastic Combined Chemotherapy ProtocolsDexamethasoneBoron CompoundsGlycineSilicates

Stichwörter der Autor:innen

FrailtyIxazomibMaintenance therapyMultiple myelomaNewly-diagnosed

Substanzen

DexamethasoneixazomibBoron CompoundsGlycinetourmalineSilicates

Autor:innen und Institutionen

  • Division of Hematology, SSD Clinical Trial in Oncoematologia e Mieloma Multiplo, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy. Electronic address: s…
  • Department of Internal Medicine, Hematology, and Oncology, University Hospital Brno, Brno, Czech Republic.
  • Department of Hematological Medicine, King's College Hospital NHS Foundation Trust, London, UK.
  • Department of Hematology and Cancer Prevention, Medical University of Silesia, Katowice, Poland.
  • Department of Blood and Marrow Transplantation, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea.
  • Hospital Beneficência Portuguesa de São Paulo, Centro de Oncologia e Hematologia da BP, São Paulo, Brazil; Hospital das Clinicas, Universidade Federal de Goiás (UFG), Hematologia, Goiânia Goiás, Brazil.

Förderung

  • AHRQ HHS
  • Takeda Pharmaceutical Company
  • Millennium Pharmaceuticals Inc

Zitieren

APA

Bringhen, S., Pour, L., Benjamin, R., Grosicki, S., Min, C. K., C de Farias, D. L., Vorog, A., Labotka, R. J., Wang, B., Cherepanov, D., Cain, L. E., Manne, S., Rajkumar, S. V., & Dimopoulos, M. A. (2023). Ixazomib Versus Placebo as Postinduction Maintenance Therapy in Newly Diagnosed Multiple Myeloma Patients: An Analysis by Age and Frailty Status of the TOURMALINE-MM4 Study. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2023.03.007

Vancouver

Bringhen S, Pour L, Benjamin R, Grosicki S, Min CK, C de Farias DL, et al. Ixazomib Versus Placebo as Postinduction Maintenance Therapy in Newly Diagnosed Multiple Myeloma Patients: An Analysis by Age and Frailty Status of the TOURMALINE-MM4 Study. Clinical Lymphoma Myeloma and Leukemia. 2023. doi:10.1016/j.clml.2023.03.007

BibTeX
@article{Bringhen2023,
  author = {Bringhen, Sara and Pour, Luděk and Benjamin, Reuben and Grosicki, Sebastian and Min, Chang-Ki and C de Farias, Danielle Leao and Vorog, Alexander and Labotka, Richard J and Wang, Bingxia and Cherepanov, Dasha and Cain, Lauren E and Manne, Sudhakar and Rajkumar, S Vincent and Dimopoulos, Meletios A},
  title = {Ixazomib Versus Placebo as Postinduction Maintenance Therapy in Newly Diagnosed Multiple Myeloma Patients: An Analysis by Age and Frailty Status of the TOURMALINE-MM4 Study},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2023},
  doi = {10.1016/j.clml.2023.03.007}
}
Kostenlos starten →